NCT07240077 Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia
| NCT ID | NCT07240077 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Mahidol University |
| Condition | Bacteremia |
| Study Type | INTERVENTIONAL |
| Enrollment | 165 participants |
| Start Date | 2026-01-08 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 165 participants in total. It began in 2026-01-08 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A double-blind randomized controlled trial comparing beta-lactam plus levofloxacin versus beta-lactam monotherapy for the treatment of Streptococcal bacteremia
Eligibility Criteria
Inclusion Criteria: 1. Adults age\>18 years 2. Blood culture positive for Streptococcus (\<72 hours before enrollment) * at least 1 bottle of S. pyogenes, S. agalactiae, S. pneumoniae, S. suis * at least 2 bottle of other Streptococci 3. Receiving or having plan of receiving beta-lactam therapy Exclusion Criteria: 1. Known allergy to beta-lactam or fluroquinolone antibiotics 2. Pregnancy or lactating mother 3. EKG with QT prolongation 4. Diagnosis of infective endocarditis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07240077 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Bacteremia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07240077 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07240077 currently recruiting?
Yes, NCT07240077 is actively recruiting participants. Contact the research team at pinyo.rat@mahidol.ac.th for enrollment information.
Where is the NCT07240077 trial being conducted?
This trial is being conducted at Bangkok, Thailand, Chiang Mai, Thailand, Nakhon Ratchasima, Thailand, Ratchaburi, Thailand.
Who is sponsoring the NCT07240077 clinical trial?
NCT07240077 is sponsored by Mahidol University. The trial plans to enroll 165 participants.